WASHINGTON — Progressive lawmakers are increasingly warning that they would forcefully oppose any effort to set up a system of arbitration to help lower drug prices, a model that would fall short of their demands to allow the federal government to negotiate with drug companies.

It’s an idea that has the implicit backing of House Speaker Nancy Pelosi (D-Calif.), whose top health policy aide has been focused on the proposal in talks with other experts. The speaker’s backing of any eventual legislation could put it on the fast track for congressional action, though no bill on the issue has yet been introduced in Congress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy